Evidence map›Paper›PMID 33806139›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors.

Mai H A Mousa, Nermin S Ahmed, Kai Schwedtmann, Efseveia Frakolaki, Niki Vassilaki, Grigoris Zoidis, Jan J Weigand, Ashraf H Abadi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mai H A MousaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt.
Nermin S AhmedDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt.
Kai SchwedtmannFaculty of Chemistry and Food Chemistry, Technische Universität Dresden, 01062 Dresden, Germany.
Efseveia FrakolakiMolecular Virology Laboratory, Hellenic Pasteur Institute, 11521 Athens, Greece.
Niki VassilakiMolecular Virology Laboratory, Hellenic Pasteur Institute, 11521 Athens, Greece.
Grigoris ZoidisDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece.ORCID 0000-0002-9442-5186
Jan J WeigandFaculty of Chemistry and Food Chemistry, Technische Universität Dresden, 01062 Dresden, Germany.ORCID 0000-0001-7323-7816
Ashraf H AbadiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt.ORCID 0000-0002-7433-261X

Funding

Science and Technology Development Fund 22848
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is an international challenge. Since the discovery of NS5A direct-acting antivirals, researchers turned their attention to pursue novel NS5A inhibitors with optimized design and structure. Herein we explore highly potent hepatitis C virus (HCV) NS5A inhibitors; the novel analogs share a common symmetrical prolinamide 2,7-diaminofluorene scaffold. Modification of the 2,7-diaminofluorene backbone included the use of (S)-prolinamide or its isostere (

Indexed as

2,7-DiaminofluoreneDAAsHCVNS5A inhibitorsprolinamidereplicon assay

Identifiers

PMID33806139
PMCPMC8064491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.